Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $116,442.70 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 2,035 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $116,442.70. Following the sale, the executive vice president now owns 5,858 shares of the company's stock, valued at approximately $335,194.76. This trade represents a 25.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jennifer Kayden Lee also recently made the following trade(s):

• On Wednesday, February 12th, Jennifer Kayden Lee sold 1,815 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $56.39, for a total value of $102,347.85.
• On Monday, February 10th, Jennifer Kayden Lee sold 4,189 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $58.91, for a total value of $246,773.99.
• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $59.43, for a total value of $85,995.21.

Rhythm Pharmaceuticals Stock Down 2.9 %

Shares of Rhythm Pharmaceuticals stock traded down $1.67 on Friday, reaching $56.07. 420,178 shares of the stock were exchanged, compared to its average volume of 463,964. The business has a 50 day moving average price of $57.10 and a two-hundred day moving average price of $53.89. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of -12.95 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.

Institutional Trading of Rhythm Pharmaceuticals

Several large investors have recently made changes to their positions in RYTM. SRS Capital Advisors Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after purchasing an additional 400 shares during the last quarter. Raleigh Capital Management Inc. purchased a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at about $28,000. SBI Securities Co. Ltd. acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at about $37,000. R Squared Ltd purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth about $44,000. Finally, State of Wyoming purchased a new position in Rhythm Pharmaceuticals during the fourth quarter valued at approximately $61,000.

Analysts Set New Price Targets

RYTM has been the subject of several recent research reports. Canaccord Genuity Group reiterated a "buy" rating and issued a $80.00 price target on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 19th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an "outperform" rating and a $76.00 price objective on the stock. JMP Securities restated a "market outperform" rating and issued a $75.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. TD Cowen upped their target price on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Finally, Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Rhythm Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.